Grant: Cat Gr: Develop./validation of new biomedical techniques/technolo.- General Pool
McGill University
$294,000.00
Next-generation stem cell culture surfaces to simplify biomanufacturing workflows
FY 2024-25
Summary
Diabetes, macular degeneration, and heart disease all have one element in common: they are chronic conditions where tissue repair is outpaced by tissue damage. Pluripotent stem cells have been proposed as potentially unlimited source of material to produce healthy cells and tissues for transplantation. Conventionally, stem cells and derived specialized cells are cultured in plastic dishes. Because stem cells can produce different types of specialized cells, most protocols apply a sorting step to purify the product before transplantation. Each added step in these protocols leads to cell losses, increased manufacturing complexity, risks of contamination, and costs. Life-saving stem cell-derived treatments will be of limited affordability to the Canadian health care system.
We propose a new cell culture platform which can not only enhance the growth of cells of interest, but also select which cells will adhere to culture surfaces. This approach could avoid cell losses and reduce culture time and complexity. The proposed technology is already protected by an international patent under licence by a McGill spinoff company. We have shown proof-of concept of this approach in simplified models but not yet in a real-world stem cell culture application. The goal of this project is to validate the technology to produce vascular cells. We chose this model because stem cell-derived vascular cells could be used to treat a wide range of medical conditions where fine blood vessels are affected. They will also be ubiquitously needed to vascularize and allow the engraftment of novel engineered tissues.
Department
Program
Cat Gr: Develop./validation of new biomedical techniques/technolo.- General Pool
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
512739
Name
Hoesli Corinne
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Catalyst Grant: Development and validation of new biomedical techniques and technologies
Projecttitle
Next-generation stem cell culture surfaces to simplify biomanufacturing workflows
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$294,000
Cihrequipment2
$6,000
Programname2
Cat Gr: Develop./validation of new biomedical techniques/technolo.- General Pool
Keyworddelim
Biomanufacturing; Bioprocess Engineering; Cell-Surface Interaction; Cellular Therapy; Neovascularization; Pluripotent Stem Cells; Surface Functionalization
Abstract
Diabetes, macular degeneration, and heart disease all have one element in common: they are chronic conditions where tissue repair is outpaced by tissue damage. Pluripotent stem cells have been proposed as potentially unlimited source of material to produce healthy cells and tissues for transplantation. Conventionally, stem cells and derived specialized cells are cultured in plastic dishes. Because stem cells can produce different types of specialized cells, most protocols apply a sorting step to purify the product before transplantation. Each added step in these protocols leads to cell losses, increased manufacturing complexity, risks of contamination, and costs. Life-saving stem cell-derived treatments will be of limited affordability to the Canadian health care system.
We propose a new cell culture platform which can not only enhance the growth of cells of interest, but also select which cells will adhere to culture surfaces. This approach could avoid cell losses and reduce culture time and complexity. The proposed technology is already protected by an international patent under licence by a McGill spinoff company. We have shown proof-of concept of this approach in simplified models but not yet in a real-world stem cell culture application. The goal of this project is to validate the technology to produce vascular cells. We chose this model because stem cell-derived vascular cells could be used to treat a wide range of medical conditions where fine blood vessels are affected. They will also be ubiquitously needed to vascularize and allow the engraftment of novel engineered tissues.
Competitiondate
202407
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Hoesli, Corinne
Approvedterm
2 ans 0 mois
Cihrcontribution2
IG~ $250,000~ $0~III~ $44,000~ $6,000~